Related Experiment Video

Updated: Jan 7, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.9K

Cyp7a1 and Cyp8b1 Downregulation Characterizes Concanavalin-A-Induced Acute Liver Injury: Insights from Multiomics

Xinlei Liu1,2, Rui Liu3, Meng Zhang3

  • 1Laboratory Animal Research Center, School of Medicine, Chongqing University, Chongqing 400044, China.

Journal of Proteome Research
|December 31, 2025
PubMed

Insights

Concanavalin-A (ConA)-induced acute liver injury (ALI) involves immune responses. This study identifies reduced bile acid enzymes (Cyp7a1/Cyp8b1) as key features, linking them to inflammation and cell death in liver damage.

Area of Science:

  • Immunology
  • Hepatology
  • Biochemistry

Background:

  • Concanavalin-A (ConA)-induced acute liver injury (ALI) is a common model for immune-mediated liver damage.
  • The precise molecular mechanisms underlying ConA-ALI are not fully understood.

Purpose of the Study:

  • To elucidate the molecular pathogenesis of ConA-induced ALI using a multiomics approach.
  • To identify key molecular features and pathways involved in ConA-ALI.

Main Methods:

  • Integrated transcriptomics, metabolomics, and proteomics to analyze ConA-ALI.
  • Network analysis to explore interactions between molecular pathways.

Main Results:

  • Significant downregulation of bile acid biosynthesis enzymes, Cyp7a1 and Cyp8b1, identified as hallmark features.
  • Suppression of Cyp7a1/Cyp8b1 correlated with altered bile acid metabolism, increased pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and hepatocyte apoptosis.
  • Multiomics network analysis revealed interplay between bile acid dysregulation, oxidative stress, and immune activation.

Conclusions:

  • Downregulation of Cyp7a1 and Cyp8b1 is a critical feature of ConA-induced ALI.
  • Bile acid dysregulation, oxidative stress, and immune activation synergistically contribute to liver injury.
  • Cyp7a1/Cyp8b1 downregulation may serve as a diagnostic marker or therapeutic target for acute hepatotoxicity.
Keywords:
acute liver injurybiomarkerconcanavalin Ainflammationliver damagemultiomics

More Related Videos

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

17.4K
Human Liver Spheroids from Peripheral Blood for Liver Disease Studies09:51

Human Liver Spheroids from Peripheral Blood for Liver Disease Studies

Published on: January 27, 2023

2.1K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
197